Inclisiran: A Review in Hypercholesterolemia.

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine
• RNA Interference Therapeutics

Background:

• Hypercholesterolemia poses a significant risk for atherosclerotic cardiovascular disease (ASCVD).
• Current lipid-lowering therapies (LLTs) like statins have limitations in efficacy and tolerability for some patients.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in regulating LDL cholesterol levels.

Purpose of the Study:

• To evaluate the efficacy and safety of inclisiran, a small interfering RNA (siRNA) targeting PCSK9 synthesis, in managing hypercholesterolemia.
• To assess inclisiran's role as an adjunct to diet and/or other LLTs, including in patients with statin intolerance.

Main Methods:

• Inclisiran is a subcutaneously administered siRNA that inhibits hepatic PCSK9 synthesis.
• Clinical trials involved administration at day 1, day 90, and then every six months.
• Evaluated LDL-C reduction in patients with hypercholesterolemia, with or without existing statin therapy.

Main Results:

• Twice-yearly inclisiran injections approximately halved LDL-C levels in patients with hypercholesterolemia.
• Efficacy was observed irrespective of concomitant statin use.
• Inclisiran demonstrated a safety and tolerability profile similar to placebo, with transient injection-site reactions being more common.

Conclusions:

• Inclisiran represents a valuable new antihyperlipidemic agent, offering an alternative or adjunct to statin therapy.
• Its infrequent dosing regimen provides a significant convenience advantage over other non-statin LLTs.
• Further confirmation of cardiovascular event reduction is pending, but inclisiran shows promise in managing hypercholesterolemia.